← back to search

Byron P. Vaughn

University of Minnesota · US
Area of research
Genetics · Infectious Diseases
Research interest
Research interests include Inflammatory Bowel Disease, Clostridium difficile and Clostridium perfringens research, Microscopic Colitis, and Gut microbiota and health.
h-index
34
citations
4,346
works
176
NIH funding
primary concept
Medicine
email

Recent publications

Oral rehydration solution for the management of fluid and electrolyte disturbances in patients with an ileostomy: A scoping review.
2026cited by 0position: contributordoi
Gastrointestinal Symptom Burden After Total Pancreatectomy With Islet Autotransplantation: A Prospective Observational Cohort Study.
2026cited by 0position: contributordoi
Impact of the IL-15 superagonist N-803 on lymphatic reservoirs of HIV
JCI Insight 2025cited by 10position: contributordoi
Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights.
2025cited by 7position: contributordoi
Novel Microbial Engraftment Trajectories Following Microbiota Transplant Therapy in Ulcerative Colitis.
2025cited by 6position: contributordoi
Nutritional optimization of fecal microbiota transplantation in humans: a scoping review.
2025cited by 6position: contributordoi
Diagnosis and Management of Clostridioides difficile in Inflammatory Bowel Disease.
2025cited by 3position: contributordoi
Metagenomic source tracking after microbiota transplant therapy.
2025cited by 3position: contributordoi
Risk Factors for Antibiotic Exposure Post-Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection: A Prospective Multicenter Observational Study.
2025cited by 0position: contributordoi
AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases
Gastroenterology 2024cited by 185position: middledoi
AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases.
2024cited by 130position: contributordoi
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn’s Disease
Clinical Gastroenterology and Hepatology 2024cited by 10position: middledoi
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus.
2024cited by 9position: contributordoi
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease.
2024cited by 6position: contributordoi
Impact of the Reverse 2-Step Algorithm for <i>Clostridioides difficile</i> Testing in the Microbiology Laboratory on Hospitalized Patients.
2024cited by 3position: contributordoi
Rethinking Faecal Microbiota Transplant for Pouchitis.
2024cited by 2position: contributordoi
Reply.
2024cited by 0position: contributordoi
Mycophenolate Mofetil-Induced Pneumatosis Intestinalis.
2024cited by 0position: contributordoi
Diagnosis and management of <i>de novo</i> inflammatory bowel disease after solid organ transplantation in the era of biologic therapy: a case series.
2024cited by 0position: contributordoi
Contribution of Common Sulfur-Containing Substrates to Hydrogen Sulfide Production By Human Gut Microbiota Using an &lt;i&gt;In Vitro&lt;/i&gt; Model Standardized For Bacterial Counts.
2024cited by 0position: contributordoi
Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
2024cited by 0position: contributordoi
A Short-Term Enteral Nutrition Protocol for Management of Adult Crohn's Disease-A Pilot Trial.
2024cited by 0position: contributordoi
Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
2023cited by 33position: contributordoi
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission
The American Journal of Gastroenterology 2023cited by 23position: middledoi
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
2023cited by 19position: contributordoi
Diagnosis of Eosinophilic Esophagitis at the Time of Esophageal Food Impaction.
2023cited by 7position: contributordoi
Kidney Biopsy Findings and Clinical Outcomes of US Veterans with Inflammatory Bowel Disease.
2023cited by 3position: contributordoi
Multicenter Study of Nonadherence to Self-Injectable Biologic Therapy in Patients With Inflammatory Bowel Disease: Risk Factors and Outcomes.
2023cited by 1position: contributordoi
Reply.
2023cited by 0position: contributordoi
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection.
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Alexander Khoruts · University of Minnesota10 papers (2019–2025) · 10 papers (2019–2025) · 8 papers (2019–2025)Michael J Sadowsky · University of Missouri6 papers (2019–2022) · 4 papers (2014–2024)Christopher Staley · University of Minnesota4 papers (2019–2025)Joshua Rhein · Centre Hospitalier Andrée Rosemon3 papers (2021–2025)Konstantinos Papamichael · Harvard University3 papers (2020–2024)Andres J Yarur · Medical College of Wisconsin3 papers (2020–2024)Amanda J. Kabage · University of Minnesota3 papers (2019–2022)William J. Sandborn · Mirati Therapeutics (United States)2 papers (2014–2015)Andrés Yarur · Medical College of Wisconsin2 papers (2023–2024)Shernan G. Holtan · Roswell Park Comprehensive Cancer Center2 papers (2019–2019)Alexandra Bruss · Medical College of Wisconsin2 papers (2023–2024)Marc K. Jenkins · Institute of Immunology2 papers (2021–2022)Margaret L. MacMillan · Masonic Cancer Center2 papers (2019–2019) · 2 papers (2019–2025)Abigail J. Johnson · Twin Cities Orthopedics2 papers (2020–2025) · 2 papers (2022–2024)Daria Kozysa · University of Minnesota2 papers (2022–2022)